|Bid||78.33 x 1200|
|Ask||78.43 x 1100|
|Day's Range||77.98 - 79.06|
|52 Week Range||68.44 - 84.56|
|Beta (5Y Monthly)||0.42|
|PE Ratio (TTM)||28.29|
|Earnings Date||Oct 28, 2021|
|Forward Dividend & Yield||2.60 (3.45%)|
|Ex-Dividend Date||Sep 14, 2021|
|1y Target Est||93.21|
These dividend stocks provide sustainable and growing dividends, which are nearly triple the S&P 500's yield.
The plan to roll out Merck & Co's promising antiviral pill to treat COVID-19 risks repeating the inequities of vaccine distribution, potentially leaving the nations with the greatest need once again at the back of the line, international health groups say. Merck on Oct 11 applied for U.S. emergency clearance of the first pill for COVID-19 after it cut hospitalizations and deaths by 50% in a large clinical trial. The medicine, made with Ridgeback Biotherapeutics, could gain authorization as soon as December.
Merck (NYSE: MRK) and Ridgeback Biotherapeutics have already made a big splash with positive results for their COVID-19 pill. However, there are are other companies nipping at their heels. In this Motley Fool Live video recorded on Oct.